Logo image of NDRA

ENDRA LIFE SCIENCES INC (NDRA) Stock Fundamental Analysis

NASDAQ:NDRA - Nasdaq - US29273B5003 - Common Stock - Currency: USD

6.36  -0.84 (-11.67%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NDRA. NDRA was compared to 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NDRA as it has an excellent financial health rating, but there are worries on the profitability. NDRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NDRA has reported negative net income.
In the past year NDRA has reported a negative cash flow from operations.
NDRA had negative earnings in each of the past 5 years.
NDRA had a negative operating cash flow in each of the past 5 years.
NDRA Yearly Net Income VS EBIT VS OCF VS FCFNDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -258.47%, NDRA is doing worse than 95.77% of the companies in the same industry.
Looking at the Return On Equity, with a value of -449.46%, NDRA is doing worse than 85.71% of the companies in the same industry.
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROIC N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
NDRA Yearly ROA, ROE, ROICNDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NDRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NDRA Yearly Profit, Operating, Gross MarginsNDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NDRA has more shares outstanding
NDRA has more shares outstanding than it did 5 years ago.
NDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NDRA Yearly Shares OutstandingNDRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
NDRA Yearly Total Debt VS Total AssetsNDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -38.50, we must say that NDRA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -38.50, NDRA is not doing good in the industry: 91.53% of the companies in the same industry are doing better.
NDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.5
ROIC/WACCN/A
WACCN/A
NDRA Yearly LT Debt VS Equity VS FCFNDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

NDRA has a Current Ratio of 5.67. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.67, NDRA belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.
NDRA has a Quick Ratio of 5.67. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
NDRA has a Quick ratio of 5.67. This is amongst the best in the industry. NDRA outperforms 84.13% of its industry peers.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
NDRA Yearly Current Assets VS Current LiabilitesNDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

NDRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.31%, which is quite impressive.
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.15% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NDRA Yearly Revenue VS EstimatesNDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2022 2025 500K 1M
NDRA Yearly EPS VS EstimatesNDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NDRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NDRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDRA Price Earnings VS Forward Price EarningsNDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDRA Per share dataNDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

A more expensive valuation may be justified as NDRA's earnings are expected to grow with 35.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.15%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NDRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENDRA LIFE SCIENCES INC

NASDAQ:NDRA (5/2/2025, 11:12:57 AM)

6.36

-0.84 (-11.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-12 2025-05-12
Inst Owners0.02%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap3.56M
Analysts82.86
Price Target76.5 (1102.83%)
Short Float %7.98%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)94.82%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-90.5
EYN/A
EPS(NY)-15.69
Fwd EYN/A
FCF(TTM)-17.11
FCFYN/A
OCF(TTM)-17.05
OCFYN/A
SpS0
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -38.5
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)84.66%
Cap/Depr(5y)76.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.22%
OCF growth 3YN/A
OCF growth 5YN/A